Jazz Pharmaceuticals plc
JAZZ
$125.22
-$0.94-0.75%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.05B | 897.84M | 1.09B | 1.05B | 1.02B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.05B | 897.84M | 1.09B | 1.05B | 1.02B |
| Cost of Revenue | 116.27M | 74.74M | 90.92M | 111.61M | 109.90M |
| Gross Profit | 929.44M | 823.10M | 997.25M | 943.36M | 913.92M |
| SG&A Expenses | 358.40M | 514.01M | 399.73M | 325.77M | 338.52M |
| Depreciation & Amortization | 162.10M | 154.45M | 158.90M | 157.46M | 155.22M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 826.74M | 923.85M | 859.61M | 794.76M | 824.38M |
| Operating Income | 218.97M | -26.01M | 228.56M | 260.21M | 199.44M |
| Income Before Tax | -735.64M | -110.35M | 133.20M | 200.52M | 137.92M |
| Income Tax Expenses | -17.17M | -17.81M | -57.91M | -14.53M | -30.65M |
| Earnings from Continuing Operations | -718.47M | -92.54M | 191.12M | 215.06M | 168.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -718.47M | -92.54M | 191.12M | 215.06M | 168.57M |
| EBIT | 218.97M | -26.01M | 228.56M | 260.21M | 199.44M |
| EBITDA | 392.98M | 138.86M | 396.98M | 425.44M | 362.48M |
| EPS Basic | -11.74 | -1.52 | 3.16 | 3.50 | 2.68 |
| Normalized Basic EPS | 1.73 | -0.82 | 1.77 | 2.04 | 1.37 |
| EPS Diluted | -11.74 | -1.52 | 3.11 | 3.42 | 2.49 |
| Normalized Diluted EPS | 1.73 | -0.82 | 1.74 | 1.98 | 1.24 |
| Average Basic Shares Outstanding | 61.19M | 60.98M | 60.54M | 61.41M | 62.88M |
| Average Diluted Shares Outstanding | 61.19M | 60.98M | 61.50M | 63.17M | 69.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |